This is a single-center, prospective, single-arm, phase II study of Osimertinib combined with Aspirin neoadjuvant therapy for resectable, EGFR mutated non-small cell lung cancer (NSCLC). It is mainly aimed at the population of patients with primary IIA- IIIA EGFR sensitive mutations that are intended to be treated with Osimertinib neoadjuvant therapy.
Patients with resectable stage IIA-IIIA lung adenocarcinoma.
Patients with EGFR sensitizing mutations (Ex19del or L858R).
Intended neoadjuvant therapy with osimertinib, with an anticipated survival expectancy of more than 3 months.
ECOG PS 0/1.
Currently receiving other anticoagulant therapy.
Previously treated with systemic therapy for NSCLC.
Other positive driver mutations, including ALK, ROS1, MET14 exon skipping, BRAF, RET, etc.
Contraindications to the use of osimertinib and aspirin.